AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00877968 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whole pea flour biscotti
Description: Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 86 g Available CHO: 51.7 g
Study NCT00877968 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Whole wheat pasta
Description: Dose was portioned so that subjects received 50 g available carbohydrate~Portion (Dry): 70 g Available CHO: 51.1 g
Study NCT00877968 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whole pea pasta
Description: Dose was portioned so that subjects received 50 g available carbohydrate Pea pasta is 30% whole pea pasta, 70 white wheat durum~Portion (Dry pasta) : 90 g Available CHO: 53.1 g
Study NCT00877968 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: White bread
Description: Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 100 g Available CHO: 50 g
Study NCT00877968 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Boiled yellow peas
Description: Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 100 g (dry) --> 250 g cooked Available CHO: 52.8 g
Study NCT03553147 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SARC-F score, handgrip test and impedancemetry
Description: Participation in the study will be offered to any patient admitted to the geriatric ward, those who meet the inclusion criteria and do not have exclusion criteria will have to complete the SARC-F questionnaire during their stay, and to do the handgrip test and impedancemetry performed by a third party. Biological data (albumin, pre-albumin and C-Reactive Protein) and anthropometric data will be collected and analyzed to determine if the patient is malnourished or not, and the results of SARC-F will be compared between these 2 groups.
Study NCT03851575 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated treatment of endocarditis
Description: For the three main bacteria species we shorten the duration of antibiotic treatment
Study NCT03851575 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual guideline therapy
Description: Usual guideline therapy
Study NCT02435134 — intervention group
Intervention type: OTHER
Intervention: no intervention
Study NCT01001182 — intervention group
Intervention type: OTHER
Intervention: non interventional
Description: non interventional
Study NCT00410358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gimatecan
Study NCT02340949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Administered I.V. at doses of 4 mg/Kg on Day 1 every 14 days. It will be supplied to sites by Sponsor as 4 ml vials at a concentration of 25 mg/ml
Study NCT02340949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluoruracil
Description: Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2
Study NCT02340949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluoruracil
Description: Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2
Study NCT02340949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU
Study NCT02340949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU
Study NCT02340949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
Study NCT02340949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
Study NCT03891225 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amniotic Membrane implantation
Description: Surgical procedure will be performed with Longemire Traverso technique. At the end of all pancreatic, biliary and duodenal anastomosis, the AM will be implanted.
Study NCT01715285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone acetate tablets will be administered orally at a total dose of 1000 mg per day until disease progression, withdrawal of consent or unacceptable toxicity.
Study NCT01715285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 5 mg capsule will be administered orally once daily until disease progression, withdrawal of consent or unacceptable toxicity.
Study NCT00309959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Description: Given IV
Study NCT00309959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01368289 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic Mucosal Resection
Description: Endoscopic Mucosal Resection of large sessile colonic polyps.
Study NCT02289092 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check-Up
Description: Parents fill out questionnaires about their child and families and then participate in a videotaped interaction with their child. Clinicians then observe the video and analyze the questionnaires to establish family needs based on supports, stress, parenting, values, and strengths. Therapists then use this information to inform the intervention process and provide feedback to families with the use of motivational interviewing. parents identify goals for parenting and/or child behavior and to connect them with resources when needed. Feedback includes a discussion of goal attainment and plans to achieve goals. Goal achievement includes options such as (a) periodic follow-up and support, (b) brief support for change on a specific topic, and (c) community referral (e.g., substance abuse referral; domestic violence referral; referral for individual therapy for depression; referral for family therapy and support for families in conflict).
Study NCT01715285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Description: All participants will receive stable regimen of ADT, that is, lutenizing hormone releasing hormone (LHRH) agonists or surgical castration according to local guidelines until disease progression, withdrawal of consent or unacceptable toxicity.
Study NCT01715285 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Androgen deprivation therapy (ADT)
Description: All participants will receive stable regimen of ADT, that is, lutenizing hormone releasing hormone (LHRH) agonists or surgical castration according to local guidelines until disease progression, withdrawal of consent or unacceptable toxicity.
Study NCT01715285 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abiraterone acetate Placebo
Description: Placebo matched to abiraterone acetate will be administered orally once daily until disease progression, withdrawal of consent or unacceptable toxicity.
Study NCT01715285 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone Placebo
Description: Placebo matched to prednisone will be administered orally once daily until disease progression, withdrawal of consent or unacceptable toxicity.
Study NCT00434434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: Aged Liquid; subcutaneous repeating dose
Study NCT00434434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: Lyophilized; subcutaneous repeating dose
Study NCT00434434 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subcutaneous repeating dose
Study NCT03883386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: 10 mg in a capsule
Study NCT03883386 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Loratadine
Description: 10 mg in a capsule
Study NCT03883386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered via capsule
Study NCT03883386 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered via capsule
Study NCT06472648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioception training exercise plan with BOSU
Description: A 5' conventional warm-up (stationary cycling and active ankle mobility exercises) was performed.~Ankle proprioception training exercise plan included:~1. A 30-second series of maintaining the single-leg stance position on the BOSU with extended knee and hip holding the ball with the arms stretched out above the head~2. A series of 10 reps on the BOSU where the subject was asked to pass from the supporting-leg hip and knee starting position to a 90º knee flexion squat, keeping the ball above their heads~3. A single series of 10 reps on the BOSU where the subject started with full limb extension of the supporting member and the ball held with both hands at chest height; from this position subjects were asked to bring the free leg from 45º hip extension to 45º hip flexion~4. 10 passes between the subject and a partner where the participants started with a total extension of the supporting limb on the BOSU and the ball held in both hands in front of them.~2' rest between exercises.
Study NCT06472648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioception training exercise plan with Blackboard (BB)
Description: A 5' conventional warm-up (stationary cycling and active ankle mobility exercises) was performed.~Ankle proprioception training exercise plan included:~1. A 30-second series of maintaining the single-leg stance position on the BB with extended knee and hip holding the ball with the arms stretched out above the head~2. A series of 10 reps on the BB where the subject was asked to pass from the supporting-leg hip and knee starting position to a 90º knee flexion squat, keeping the ball above their heads~3. A single series of 10 reps on the BB where the subject started with full limb extension of the supporting member and the ball held with both hands at chest height; from this position subjects were asked to bring the free leg from 45º hip extension to 45º hip flexion~4. 10 passes between the subject and a partner where the participants started with a total extension of the supporting limb on the BB and the ball held in both hands in front of them.~2' rest between exercises.
Study NCT02359240 — intervention group
Intervention type: PROCEDURE
Intervention: therapy according to SSC guidelines and muscle biopsy
Description: Septic patients will be treated according to the international guidelines for management of severe sepsis and septic shock 2012. Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing.150-300 mg muscle (wet weight) was routinely obtained , which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein
Study NCT02359240 — intervention group
Intervention type: PROCEDURE
Intervention: standard surgery for femoral fracture and muscle biopsy
Description: Patients with femoral fracture will under standard surgery for fracture fixation. Percutaneous needle muscle biopsies will be performed. Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing.150-300 mg muscle (wet weight) was routinely obtained , which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein
Study NCT03091439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Description: Participants received Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1 and on Day 8.
Study NCT03091439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants received an antibiotic consistent with standard of care (SOC) for osteomyelitis based on Investigator judgment. The duration of treatment was 4-6 weeks.
Study NCT01409668 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. Amylovorus
Description: L. Amylovorus
Study NCT02947087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolastin-C
Description: Patients will receive Prolastin-C at 60mg/kg on day 0, 7, 14, and 21 days of transplantation
Study NCT02947087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive saline on day 0, 7, 14, and 21 days of transplantation
Study NCT03141697 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon Dioxide
Description: Insufflation of Carbon Dioxide
Study NCT03141697 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Room air
Description: Insufflation of room air
Study NCT01579279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-652 6 mg
Description: 6 mg capsules
Study NCT01579279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-652 12 mg
Description: 12 mg capsules
Study NCT01579279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-652 12 mg - 18 mg
Description: 12 mg - 18 mg capsules
Study NCT01579279 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT01409668 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. Fermentum
Description: L. Fermentum
Study NCT01579279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Duloxetine capsules
Study NCT04135768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wrist joint haematoma washout
Description: After plating of the distal radius is performed, a small incision is made on the wrist joint capsule. This is the portal for fluid efflux. An intravenous cannula is used to puncture the wrist joint capsule adjacent to the first incision and normal saline is infused through this cannula into the wrist joint. The infusion continues until the fluid efflux from the first portal is clear and no longer blood stained. This will be the point at which the washout is considered to be complete.
Study NCT04135768 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Volar locking plate insertion of the distal radius
Description: An anatomical locking plate is applied to the distal radius fracture using screws
Study NCT00639184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early intervention counseling
Description: Bi-monthly home visits by counselor
Study NCT00639184 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health education counseling
Description: World Health Education health education counseling program at home visits,twice per month
Study NCT04156698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel is a chemotherapy drug.
Study NCT04156698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is a chemotherapy drug.
Study NCT04156698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is a chemotherapy drug.
Study NCT04156698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.
Study NCT04135768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Volar locking plate insertion of the distal radius
Description: An anatomical locking plate is applied to the distal radius fracture using screws
Study NCT01983254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: coping skills training
Description: 6-session coping skills training program delivered by telephone w/ web augmentation
Study NCT04562376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity resistance training
Description: The program consists of high-intensity resistance training for 60 minutes twice a week (group A) during 12 weeks
Study NCT01983254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: education program
Description: web-based, ICU-specific education program
Study NCT00697697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.135mg MAP0010
Description: 0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
Study NCT04562376 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low frequency of high-intensity resistance training
Description: The program consists of high-intensity resistance training for 60 minutes once a week (group B) during 12 week
Study NCT04184141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyzine Hydrochloride
Description: Hyroxyzine hydrochloride is given to the patient one hour before surgery.
Study NCT04184141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam tablet
Description: Alprozolam is given to the patient one hour before surgery.
Study NCT04184141 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo candy
Study NCT01101178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reformulated OXY (oxycodone HCl)
Description: Reformulated OXY 80-mg tablet x 1 dose taken with food.
Study NCT01101178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Original OxyContin® (OXY) (oxycodone HCl)
Description: Original OxyContin® (OXY) 80-mg tablet x 1 dose taken with food.
Study NCT00522834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elesclomol (STA-4783)
Description: 213 mg/m2 Elesclomol (STA-4783) plus 80 mg/m2 paclitaxel administered intravenously once a week for the first 3 weeks of a 4 week cycle. Number of cycles: Until progression or unacceptable toxicity develops
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dopamine
Description: Cardiovascular drug used to treat intraoperative hypotension
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoproterenol
Description: Cardiovascular drug used to treat intraoperative hypotension
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoproterenol
Description: Cardiovascular drug used to treat intraoperative hypotension
Study NCT00522834 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: 80 mg/m2 paclitaxel alone administered intravenously once a week for the first 3 weeks of a 4 weeks cycle. Number of cycles: Until progression or unacceptable toxicity develops
Study NCT02608619 — intervention group
Intervention type: RADIATION
Intervention: F-choline PET Scan
Study NCT02608619 — intervention group
Intervention type: DEVICE
Intervention: FDG-PET
Study NCT00697697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25mg MAP0010
Description: 0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
Study NCT02608619 — intervention group
Intervention type: PROCEDURE
Intervention: biopsy
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milrinone
Description: Cardiovascular drug used to treat intraoperative hypotension
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milrinone
Description: Cardiovascular drug used to treat intraoperative hypotension
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: Cardiovascular drugs used to treat intraoperative hypotension
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Cardiovascular drugs used to treat intraoperative hypotension
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: Cardiovascular drug used to treat intraoperative hypotension
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Description: Cardiovascular drug used to treat intraoperative hypotension
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: Cardiovascular drug used to treat intraoperative hypotension
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Description: Cardiovascular drug used to treat intraoperative hypotension
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: Cardiovascular drug used to treat intraoperative hypotension
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: Cardiovascular drug used to treat intraoperative hypotension
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Chloride 0.9%
Description: Intravenous fluid used to treat intraoperative hypotension
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: Intravenous fluid used to treat intraoperative hypotension
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer's lactate
Description: Intravenous fluid used to treat intraoperative hypotension
Study NCT00858988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: 100mg of rifaxin for 7 consecutive days, twice daily
Study NCT00858988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily for 7 consecutive days